Journal article
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy
SJ Hume, DK Wong, MF Yuen, K Jackson, S Bonanzinga, S Vogrin, SAL Hall, GS Burns, PV Desmond, V Sundararajan, D Ratnam, MT Levy, JS Lubel, AJ Nicoll, SI Strasser, W Sievert, MC Ngu, M Sinclair, C Meredith, G Matthews Show all
Liver International | WILEY | Published : 2024
DOI: 10.1111/liv.16029
Abstract
Background and Aims: Accurate biomarkers to predict outcomes following discontinuation of nucleos(t)ide analogue (NA) therapy are needed. We evaluated serum hepatitis B core-related antigen (HBcrAg) level as a biomarker for predicting outcomes after NA discontinuation. Methods: Patients with HBeAg-negative chronic hepatitis B (CHB) without cirrhosis were enrolled in a prospective trial evaluating clinical outcomes until 96 weeks after NA discontinuation. End of treatment (EOT) and off-treatment levels of serum HBcrAg, HBsAg, HBV RNA and HBV DNA were used to predict key clinical outcomes including hepatitis flare (ALT ≥5 × ULN and HBV DNA > 2000 IU/mL). The SCALE-B score was calculated for th..
View full abstractGrants
Awarded by University of Melbourne
Funding Acknowledgements
The clinical study was supported by the National Health and Medical Research Council of Australia Project Grant 1 066 536. AJT received funding from the National Health and Medical Research Council of Australia (MRFF Practitioner Fellowship 1142976). The cobas (R) 6800/8800 HBV RNA Investigational Assay reagents used for measuring serum HBV RNA were provided by Roche Molecular Systems, Inc.